Y mAbs Therapeutics — Q2 2024 Earnings Presentation
20 slides from Y mAbs Therapeutics's earnings presentation, Aug 12, 2024
Slide 1: Q2 2024 Financial Results and Corporate Update
Q2 2024 Financial Results and Corporate Update August 12, 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre
Slide 3: Intro and Company Overview - Mike Rossi
Mike Rossi President and CEO Intro and Company Overview 3
Slide 4: Agenda
Agenda Company Overview 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Sales 2 Sue Smith, Chief Commercial Officer Naxitamab Development Program 3 Vignesh Rajah, Chief Medical Officer Q2 2024 Financials 4 Peter Pfreundschuh, Chief Financial Officer Q&A 5 All 4
Slide 5: DANYELZA Highlights
DANYELZA Highlights • Q2 2024 total DANYELZA net product revenues of $22.8M, 10% YoY • 1H 2024 total DANYELZA net product revenues of $42.2M, 3% YoY • DANYELZA added to 2 new hospital formularies in the U.S. in Q2 2024 • Remains a leading anti-GD2 therapy in the U.S. • Increased ex-U.S. revenue
Slide 6: GD2-SADA Phase 1 Clinical Trial (Study 1001): Dosing Patients in Part A
GD2-SADA Phase 1 Clinical Trial (Study 1001): Dosing Patients in Part A Theranostic approach using a 30 mCi 177Lu-DOTA imaging dose before exposing to therapeutic dose Part A* Part B Part C Inclusion Criteria N ≈ 15 – 18 N ≈ 9 – 12 5 cycles 177Lu-DOTA therapeutic • ECOG performance GD2-SADA protein
Slide 7: Ongoing GD2-SADA Phase 1 Clinical Trial (Study 1001): Part A Overview
Ongoing GD2-SADA Phase 1 Clinical Trial (Study 1001): Part A Overview TRIAL UPDATE PART A DATA ELEMENTS › Solid tumors (SCLC, malignant melanoma, sarcomas) › Completed Cohorts 1 through 4; currently in Cohort 5* • Optimal and safe GD2-SADA protein dose › 17 patients dosed to date* • Dosing interval
Slide 8: CD38-SADA Phase 1 Clinical Trial (Study 1201): Planned Design
CD38-SADA Phase 1 Clinical Trial (Study 1201): Planned Design Theranostic approach using CD38 positivity on IHC and 177Lu-DOTA organ dosimetry before repeat dosing in patients with relapsed or refractory non-Hodgkin Lymphoma Part A Part B N = 12 – 15 N = 12 – 15 Inclusion Criteria TRIAL UPDATE • R/R
Slide 9: Global DANYELZA Sales - Sue Smith
Sue Smith Chief Commercial Officer Global DANYELZA Sales 9
Slide 10: Q2 2024 DANYELZA Global Commercial Update
Q2 2024 DANYELZA Global Commercial Update • Q2 2024 Total DANYELZA net product revenues of $22.8M, 10% YoY • Q2 2024 U.S. DANYELZA net product revenues of $15.2M, 4% YoY • Q2 2024 Ex-U.S. DANYELZA net product revenues of $7.6M, 55% YoY • 65 U.S. accounts* since initial launch; 7 new accounts ad
Slide 11: Naxitamab Development Program - Vignesh Rajah
Vignesh Rajah Chief Medical Officer Naxitamab Development Program 11
Slide 12: Ongoing Naxitamab Clinical Trials
Ongoing Naxitamab Clinical Trials • Multi-center Phase 2 trial • Phase 2 BCC multi-center • ISS Phase 1b/2 trial • Randomized Phase 2 trial investigating naxitamab trial evaluating naxitamab investigating TGFβ NKs, evaluating efficacy and in patients with relapsed + standard induction gemcitabine +
Slide 13: Q2 2024 Financials - Peter Pfreundschuh
Peter Pfreundschuh Chief Financial Officer Q2 2024 Financials 13
Slide 14: Key Q2 2024 and 1H Financial Highlights: Revenue
Key Q2 2024 and 1H Financial Highlights Revenue Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Net product revenue $22.8 M $20.8 M Net product revenue $42.2 M $41.0 M License revenue – – License revenue $0.5 M – Total revenue $22.8 M $20.8 M Total revenue $42. 7 M $41.0 M Ne
Slide 15: Key Q2 2024 and 1H Financial Highlights: Operating Expenses
Key Q2 2024 and 1H Financial Highlights Operating Expenses Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Cost of goods sold $3.0 M $4.6 M Cost of goods sold $5.1 M $6.7 M License royalties – – License royalties $0.05 M – Research & development $12.3 M $12.1 M Research & dev
Slide 16: Key Q2 2024 and 1H Financial Highlights: Net Loss
Key Q2 2024 and 1H Financial Highlights Net Loss Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Net loss $(9.2) M $(6.3) M Net loss $(15.9) M $(12.7) M Net loss per basic, diluted share $(0.21) $(0.14) Net loss per basic, diluted share $(0.36) $(0.29) Net loss Net loss 47%
Slide 17: Key Q2 2024 Financial Highlights
Key Q2 2024 Financial Highlights Responsible stewards of capital As of Six months ended Jun 30, Jun 30, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $77.8 M $78.6 M Cash use $0.8 M $17.9 M Anticipated cash runway Cash use into 2027* 96% YoY *This estimate reflects the Company's current bu
Slide 18: Financial Guidance for Full Year 2024
Financial Guidance for Full Year 2024 UPDATED $87 million to $95 million Total Net Revenues: REITERATE $115 million to $120 million Total Expected Operating Expenses: REITERATE $15 million to $20 million Total Expected Cash Burn: Cash and cash equivalents anticipated to support operations as current
Slide 19: Q&A
Q&A Mike Rossi Sue Smith President and Chief Commercial Officer Chief Executive Officer Vignesh Rajah, MBBS, Peter Pfreundschuh DCH, MRCP Chief Financial Officer Chief Medical Officer 19
Slide 20: Thank You
Thank You